Wera

Quick links to important sections

Wera

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Wera

Property Description
Active ingredient Ethinyl Estradiol and Norethisterone
Form Oral tablet
Pharmacological class Combined Oral Contraceptive (COC)
Common use Prevention of pregnancy (Birth Control)
Origin Synthetic steroid compounds

Wera is a fixed-dose pharmaceutical combination that belongs to the pharmacological class of Sex Hormone Combinations and is specifically categorized as a Combined Oral Contraceptive (COC). Its fundamental purpose is to function as a highly reliable, systemic method of birth control for women, achieved through the coordinated hormonal action of its two active agents. As a prescription-only medication, Wera requires professional authorization for use.

What Type of Medicine is Wera?

Wera is a preparation whose primary function is the prevention of pregnancy, classified under the pharmacological heading of Combined Oral Contraceptives. The combination of an estrogenic agent, Ethinyl Estradiol, and a progestational agent, Norethisterone, is a standard formulation in modern hormonal birth control. This specific formulation is widely recognized by health authorities as a dependable and well-studied approach to preventing conception.

Composition and Origin: The Synthetic Hormones

The active ingredients in Wera are Ethinyl Estradiol and Norethisterone, both of which are synthetic steroid compounds formulated for oral intake. Ethinyl Estradiol serves as the potent synthetic estrogen component, while Norethisterone is a well-established second-generation progestin. These specific compounds are designed to be orally active and readily absorbed, which is essential for the reliability of the oral tablet form. The medication’s specific synthetic composition guarantees consistent daily delivery of the hormones required for its contraceptive efficacy.

How Does Wera Prevent Pregnancy?

Wera prevents conception through a multi-faceted physiological action that systematically interferes with the natural menstrual cycle. The combined hormones primarily work by inhibiting ovulation, meaning the ovaries are prevented from releasing an egg each month, which is the necessary first step for pregnancy. Additionally, the drug induces changes to the body's environment, such as thickening the cervical mucus, providing a reliable and systemic approach to achieving contraceptive reliability.

Regulatory References

  1. Ethinyl Estradiol and Norethindrone (Oral Contraceptives)

What side effects are possible with Wera?

Possible Side Effects and Safety Information

The safety profile of Wera (Ethinyl Estradiol and Norethisterone) is organized by regulatory authorities based on the frequency and the physiological system affected. Most patient-reported events are classified as Common adverse reactions, typically observed with high-frequency in clinical data. Less frequent, yet more serious, reactions are categorized separately under high-level warnings.

Officially Documented Adverse Reactions

Adverse reactions that are frequently encountered in clinical use include headache, nausea, breast tenderness or pain (mastodynia), abdominal pain, weight gain, and mood disturbances. Irregular uterine bleeding, such as spotting or breakthrough bleeding, is also a Common side effect, often reported during the initial three cycles of therapy.

Reactions are grouped into System-Organ Classes (SOCs) for regulatory clarity, including the Vascular, Hepatobiliary, Gastrointestinal, and Reproductive Systems. Increased blood pressure is classified as Uncommon.

Serious Adverse Reactions and Safety Constraints

Official regulatory documentation highlights the risk of Serious Adverse Reactions, classified as Rare. These include Venous Thromboembolism (VTE), such as Deep Vein Thrombosis and Pulmonary Embolism, and Arterial Thromboembolism (ATE), encompassing Myocardial Infarction and Stroke. The risk of VTE is noted to be highest during the first year of use.

Population-Specific Safety Constraints are mandated for certain groups. The medication is constrained for use in smokers aged 35 years and older due to a significantly elevated risk of serious cardiovascular events. Furthermore, use should be deferred for at least four weeks in non-breastfeeding women following delivery due to VTE risk. The medication does not protect against HIV or other sexually transmitted diseases.

Overdose and Emergency Response

Official Regulatory Overdose Profile

The official regulatory documentation classifies the acute oral ingestion of excessive doses of Wera (Ethinyl Estradiol and Norethisterone) as having a low acute toxicity profile. Serious or life-threatening toxic effects are not expected as a direct consequence of acute overdose, establishing a regulatory focus on managing expected hormonal manifestations.

The documented clinical manifestations of overdose are typically extensions of the medicine's known hormonal activity. These presentations are formally recognized:

  • Gastrointestinal Effects: Nausea and vomiting are the most frequently documented acute symptoms following excessive ingestion.
  • Hormonal Manifestations: Withdrawal bleeding, which may present as vaginal spotting or heavier bleeding, may occur in female patients several days after the excessive dosage has been taken. Regulatory labeling notes that this manifestation can occur even in pre-pubertal female patients who have accidentally ingested the medicine.

Required Emergency Actions

Regulatory guidance mandates specific actions in the event of suspected overdose:

  • Immediate consultation is required: Seek immediate medical attention or contact a local poison control center for specific guidance.
  • Treatment is strictly symptomatic and supportive. The official label confirms that no specific antidote is known for the reversal of the effects of this combination. Clinical observation and monitoring of vital signs and symptoms may be required in a clinical setting.

Therapeutic Uses of Wera

What Wera Treats: Main Uses and Benefits

Wera (Ethinyl Estradiol and Norethisterone) is primarily used to provide reliable contraception for pregnancy prevention. This fundamental use helps address symptom clusters that create noticeable physiological strain, which supports the patient's planning in long-term family considerations.

Beyond contraception, the medication is commonly used to help manage symptoms related to systemic imbalance and conditions characterized by periods of heightened symptomatic discomfort. This includes painful menstrual periods (dysmenorrhea), heavy menstrual bleeding (menorrhagia), irregular periods, and symptoms of conditions like PMDD and PCOS.

The medication is relevant in clinical settings marked by hormonally-mediated manifestations, particularly moderate acne vulgaris. This application may support the patient during difficult episodes by easing the distress related to these visible, disruptive symptoms. Long-term therapeutic use is also associated with a reduction in the risk of developing ovarian and endometrial cancers, and is associated with a reduced risk of developing functional ovarian cysts.

“Wera is applied when additional symptomatic support is needed, contributing to improved comfort and stability during symptomatic phases.”

Quick Fact: Relief for Cycle Irregularity
The medication is used for managing menstrual cycle regularity, which may assist patients by helping with cycle predictability and easing the overall symptom load.

Regulatory References

  1. MedlinePlus overview on Ethinyl Estradiol and Norethindrone

Eligibility and Restrictions for Use

Wera is officially indicated for use by females of reproductive potential to prevent pregnancy. Eligibility is strictly defined by regulatory guidelines that establish critical non-eligibility rules based on health status and age-related risk.

Populations Who Must Not Use Wera (Contraindications)

Official labeling mandates that Wera is contraindicated and must not be used in the presence of certain high-risk conditions, including:

  • A history of or current thrombotic or thromboembolic disorders (e.g., deep vein thrombosis, pulmonary embolism, stroke, or heart attack).
  • Known or suspected pregnancy, or use to test for pregnancy.
  • Active liver disease, hepatic adenomas, or estrogen-dependent neoplasia (such as breast cancer).
  • Migraines with aura or uncontrolled hypertension.
  • Females over 35 years of age who smoke.

Official Eligibility Restrictions

Age Group / Condition Eligibility Status Specific Limitation
Adolescents Use not established Safety and efficacy are not established in adolescents under 18 years of age.
Postpartum Women Restricted Use Should not be initiated earlier than 4 weeks after delivery due to increased thromboembolic risk.
Breastfeeding Not Recommended Use may reduce the quantity and alter the composition of breast milk.
Major Surgery Contraindicated Must be stopped 4 weeks before and for 2 weeks after any major surgery involving prolonged immobilization.

What should I know about interactions with other medicines?

Wera Interactions with other medicines and products

The interaction profile of Wera (Ethinyl Estradiol and Norethisterone) is defined by pharmacokinetic and pharmacodynamic mechanisms as documented in regulatory sources.

Documented Interaction Classifications

Classification Key Examples and Mechanism
Contraindicated Combinations Certain Hepatitis C Virus (HCV) drug combinations (e.g., Ombitasvir/paritaprevir/ritonavir) are formally prohibited due to the risk of significant ALT enzyme elevations.
Enzyme Induction Strong enzyme inducers, such as the herbal product St. John’s Wort and some anti-epileptics (e.g., Phenytoin), increase the clearance of Wera’s hormones, leading to a documented reduction in contraceptive effectiveness.
Exposure Modification Co-administration with certain drugs (e.g., Atazanavir) may inhibit metabolism, causing an increase in the plasma concentrations (AUC) of Wera's hormonal components.
Pharmacodynamic Interference Wera can significantly decrease the plasma concentrations of co-administered medicines, notably Lamotrigine, through the induction of glucuronidation

.

Administration Constraints

Certain substances require timing separation or restrictions as specified in regulatory labeling. The initiation of Wera must be deferred until 5 days after administration of Ulipristal acetate (emergency contraception). Additionally, Wera requires separation of administration from the bile acid sequestrant Colesevelam to prevent interference with gastrointestinal absorption. Population-specific notes document that hormones may be poorly metabolized in individuals with hepatic impairment.

Mechanism of Action

Wera is a combination hormonal agent containing the estrogen ethinyl estradiol and the progestin norethindrone.

Its pharmacodynamic action primarily targets the hypothalamic-pituitary-ovarian axis. The steroid hormones act as agonists at estrogen receptors (ERs) and progesterone receptors (PRs), respectively.

Intracellularly, these interactions lead to a sustained, negative feedback on the hypothalamus, modulating the pulsatile release of gonadotropin-releasing hormone (GnRH). This downstream cascade inhibits the secretion of the pituitary gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH).

The systemic consequence is the suppression of the LH surge, preventing ovulation by blocking the final maturation and rupture of the ovarian follicle.

Additionally, norethindrone alters the physicochemical properties of the cervical mucus, increasing its viscosity, thereby impeding sperm migration through the cervical canal. It also induces endometrial changes, including glandular atrophy and stromal decidualization, which modifies the uterine lining environment.

Dosage and Administration Information

The administration of Wera (Ethinyl Estradiol and Norethisterone), a Combined Oral Contraceptive, is governed by a strict, daily, cyclic regimen to ensure reliable use. The official instructions define the required route, dose, and sequential timing for the 28-day course.


Administration and Dosing Schedule

Scope Element Official Instruction
Route of administration The medicine is for oral administration only, taken as one tablet once per day.
Dosing schedule The regimen follows a 28-day cycle, consisting of either 21 or 24 consecutive days of active (hormonal) tablets, followed by 7 or 4 days of non-hormonal (placebo) tablets or a tablet-free interval.
Timing in relation to meals The tablet may be administered without regard to meals.

Procedural Instructions and Constraints

The most essential aspect of usage is consistency: the tablet must be taken at the same time every day. The medication is supplied in a blister pack, and tablets must be taken in the order directed to maintain the correct hormonal sequence throughout the cycle.

Official Starting Protocol

Administration may begin using the Day 1 Start (first day of menstruation) or the Sunday Start (first Sunday after menstruation begins). If the medicine is not started on Day 1, a non-hormonal back-up method must be used for the first seven consecutive days of use to ensure effectiveness.

Use Over Time

After completing the 28-day course, the subsequent cycle must begin immediately, maintaining continuous, repeating use for as long as contraception is desired. Specific label guidance exists for managing scenarios such as a missed active tablet or events like vomiting or severe diarrhea that could compromise drug absorption.

Recent Clinical Evidence

Research evidence / Overview of Studies for Wera

The available research on Wera (Ethinyl Estradiol/Norethisterone) provides context regarding how this type of combined oral contraceptive (COC) was studied for its intended uses in clinical trials and large-scale observational settings. This overview describes the research structures, the outcomes that were measured, and areas where evidence is still emerging. Research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were observed.

Evidence for Pregnancy Prevention (Contraception)

The evidence base for combined oral contraceptives like Wera is primarily rooted in decades of large, multicenter open-label trials and population-based observational studies. Research has examined the core outcome of pregnancy prevention using standardized metrics, such as the Pearl Index, which measures the number of pregnancies per 100 women using the method for one year. Studies monitored measurements of contraceptive outcomes when the medicine was observed in clinical settings, reflecting outcomes under conditions of "perfect use." Research so far indicates that the measured rates under perfect use may differ from the rates observed in everyday, real-world conditions ("typical use"). Data for certain groups remain insufficient, such as for women with a significantly high Body Mass Index (BMI), where research highlights areas of limited information.

Evidence for Managing Menstrual Symptoms

The use of this medicine was evaluated in women experiencing conditions characterized by episodic manifestations such as painful menstrual periods (dysmenorrhea). Research has explored short-term symptom changes, often through Randomized Controlled Trials (RCTs). Research examined the medicine's use in studies exploring outcomes related to physical discomfort. However, a key limitation is that follow-up durations were limited in many of these clinical trials, typically lasting only three to six months. This means that long-term symptom patterns are not fully established.

Long-Term Observational Research and Associated Outcomes

The study of long-term outcomes relies on vast population-based observational research, including Prospective Cohort Studies. Research explored the association between a history of COC use (as a class) and the incidence of epithelial ovarian cancer and endometrial cancer compared to women who have never used them. Studies consistently reported an association between a history of COC use and measured risk outcomes (Odds Ratio/Hazard Ratio) related to these cancers. This reported pattern was observed in some studies to be sustained for a period even after the medicine's use had stopped.

Key Studies & References

  1. Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Dysmenorrhea (Clinical Trial NCT00212342) - (Norethisterone/Ethinylestradiol combination)
  2. Combined hormonal contraceptives and the risk of venous thromboembolism (VTE) - UKCPA Handbook (Cited for VTE risk with Norethisterone/Ethinylestradiol)

Frequently Asked Questions (FAQ)

Common questions about Wera (FAQ)


Q: Can people with kidney conditions take Wera?

Official guidelines on the use of combined hormonal contraceptives state that restriction or caution may be necessary for individuals with certain health issues, including chronic renal disease (long-term kidney failure) that is associated with high blood pressure. These official criteria help guide medical decisions regarding the appropriateness of Wera's use.


Q: Is it true that Wera can affect blood pressure?

Yes, official regulatory documents describe the possibility of increased blood pressure (hypertension) as an uncommon effect associated with this class of medicine. Regulatory information advises that blood pressure monitoring may be necessary during the use of combined oral contraceptives.


Q: Is Wera available as a generic version?

The active components of Wera, Ethinyl Estradiol and Norethindrone, are a standard and well-studied combination of hormones. Because this combination is a standard formulation, many health authorities have approved the active ingredients for use in various generic formulations.


Q: What should be done if a dose of Wera is forgotten?

Official guidance provides specific procedural steps for managing missed doses of hormonal contraceptives. The action needed depends on factors like how many pills were missed and where in the cycle the missed doses occurred. Following these instructions helps to maintain contraceptive reliability.


Q: Can Wera be stopped suddenly, or does it require tapering off?

Unlike some other medications, hormonal contraceptives are not generally associated with a need for a gradual dose reduction or 'tapering off.' According to official patient information, use can typically be discontinued at any time.


Q: Do people with a history of heart issues need to be cautious with Wera?

Official regulatory documents indicate that Wera is contraindicated (must not be used) in individuals with a history of or current ischemic heart disease or prior thrombotic events (like a heart attack or stroke). These restrictions are consistent with official safety information regarding this class of medication.


Q: How do doctors decide on the starting amount of Wera?

Wera is a fixed-dose combination, meaning the amount of each hormone in the active tablets does not vary. Instead of adjusting the dose, initial use begins according to an official protocol, such as utilizing the Day 1 Start or Sunday Start method.


Q: What should be checked on lab tests while taking Wera?

Official labeling highlights the need for caution in active liver disease and in specific drug combinations that may be associated with ALT enzyme elevation (a marker of liver function). This may indicate when lab monitoring is necessary.


Q: Is Wera appropriate for managing acute (short-term) symptoms?

The main intended use of Wera is the long-term prevention of pregnancy through the consistent, regulated suppression of ovulation. While this class of medicine may be studied for managing chronic or episodic symptoms, it is not primarily intended for the treatment of acute, short-term health issues.


Q: How common is it to switch from one medicine to Wera?

Official patient instructions include specific procedural steps for switching from another hormonal method to Wera. These steps are designed to ensure that continuous contraceptive protection is maintained during the transition period.


Q: How quickly can someone expect to feel the effects of Wera?

Contraceptive effectiveness is not considered fully established until seven consecutive days of active tablets have been taken correctly. While the hormones begin acting quickly, subjective changes related to side effects may be felt sooner. The time until desired effects, such as relief from menstrual symptoms, can vary.


Q: Does Wera start working immediately after taking it?

The medicine begins acting on the body’s hormonal axis shortly after intake. However, official guidance requires a non-hormonal back-up method (like condoms) for the first seven consecutive days of the first cycle to ensure reliable contraceptive protection.


Q: How long does one dose of Wera stay active in the body?

Wera is designed for a once-daily regimen, and its effectiveness relies on the tablet being taken at the same time every day. This consistent, daily intake is necessary to maintain the continuous hormone levels required to prevent pregnancy.


Q: Is it normal to feel a change in the first few days of taking Wera?

Official documents describe side effects such as nausea and headache as common upon starting the medicine. Furthermore, irregular uterine bleeding (spotting or breakthrough bleeding) is often reported during the initial three cycles of use.


Q: What is the difference between Wera and other medicines that treat the same condition?

Wera is a Combined Oral Contraceptive (COC) containing a synthetic estrogen and a second-generation progestin (Norethindrone). Other birth control options also exist that use different doses of these components or newer classes of progestin. This difference in composition may affect the side effect and interaction profile.


Q: Do the side effects of Wera go away over time?

Official patient information indicates that some common side effects, particularly irregular uterine bleeding (spotting), may lessen or resolve after the first few cycles of use. Consistent use over the initial period is often followed to see if these effects diminish.


Q: Are there any specific vitamins or supplements that interact with Wera?

Yes, official labeling explicitly documents that the herbal product St. John’s Wort can interfere with how your body processes Wera. This interaction can reduce the effectiveness of the contraceptive, and official information notes that co-administration may reduce the contraceptive's effectiveness.


Q: Is Wera linked to any changes in mood or sleep?

Official adverse reaction lists classify mood disturbances as a Common side effect associated with the use of this medicine. Official guidance often recommends reporting unexpected or severe changes in mood to a healthcare professional.


Q: Why is Wera often taken at a specific time of day?

The official instruction to take the tablet at the same time every day is a requirement for reliable use. This practice is necessary to maintain the consistent, systemic hormone levels required throughout the cycle to ensure contraceptive effectiveness.

How should Wera be stored and disposed of?

How to Store and Dispose of Wera?

This information reflects the official storage and disposal requirements defined by government regulatory agencies for the product's active components.

Official Storage Requirements

  • Temperature and Environment: The medication must be stored at room temperature (20°C to 25°C or 68°F to 77°F) and kept away from excess heat and moisture.
  • Containment: Keep the product in the original container, tightly closed. The topical solution must be stored away from heat and ignition sources.
  • Child Safety: It is required to store the medication out of the reach of children at all times.
  • Handling: To avoid exposure, individuals should not crush tablets or open capsules. Hands must be washed after handling topical solutions.

Official Disposal Instructions

  • Preferred Method: The unused or expired medicine should be disposed of using an official drug take-back program.
  • Household Disposal: If a take-back program is unavailable, the medicine must be mixed with an unappealing substance (like dirt or used coffee grounds), placed in a sealed container, and thrown in the household trash. Do not flush.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Wera found in:

A-Z Index: